Irinotecan plus fluorouracil/folinic acid: increased risk of death?

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2001年 / 882卷 / 1期
关键词：
Fluorouracil; Irinotecan; Oxaliplatin; Leucovorin; Folinic Acid;
D O I：
10.2165/00128415-200108820-00010
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：6 / 6
相关论文
共 50 条
  • [31] Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
    Gubanski, Michael
    Johnsson, Anders
    Fernebro, Eva
    Kadar, Lianna
    Karlberg, Ingegerd
    Flygare, Petra
    Berglund, Ake
    Glimelius, Bengt
    Lind, Pehr A.
    GASTRIC CANCER, 2010, 13 (03) : 155 - 161
  • [32] Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study
    Endlicher, Esther
    Schnoy, Elisabeth
    Troppmann, Martina
    Rogler, Gerhard
    Messmann, Helmut
    Klebl, Frank
    Gelbmann, Cornelia
    Kullmann, Frank
    DIGESTION, 2016, 93 (03) : 229 - 233
  • [33] Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer
    Madajewicz, Stefan
    Waterhouse, David M.
    Ritch, Paul S.
    Khan, M. Qaseem
    Higby, Donald J.
    Leichman, Cynthia G.
    Malik, Sandeep K.
    Hentschel, Patricia
    Gill, John F.
    Zhao, Luping
    Nicol, Steven J.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 772 - 778
  • [34] Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma -: A phase I study
    Garufi, G
    Dogliotti, L
    D'Attino, RM
    Tampellini, M
    Aschelter, AM
    Pugliese, P
    Perrone, M
    Nisticó, C
    Comis, S
    Terzoli, E
    CANCER, 2001, 91 (04) : 712 - 720
  • [35] Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin)
    Gubanski, M.
    Glimelius, B.
    Lind, P. A.
    MEDICAL ONCOLOGY, 2014, 31 (04)
  • [36] Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
    Andreas Teufel
    Silke Steinmann
    Jürgen Siebler
    Christiane Zanke
    Herbert Hohl
    Bernd Adami
    M Schroeder
    O Klein
    Thomas Höhler
    Peter R Galle
    Michael Heike
    Markus Moehler
    BMC Cancer, 4
  • [37] Bimonthly Chemotherapy with Oxaliplatin, Irinotecan, Infusional 5-Fluorouracil/Folinic Acid in Patients with Metastatic Colorectal Cancer Pretreated with Irinotecan- or Oxaliplatin-Based Chemotherapy
    Nobili, S.
    Checcacci, D.
    Filippelli, F.
    Del Buono, S.
    Mazzocchi, V.
    Mazzei, T.
    Mini, E.
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (05) : 622 - 631
  • [38] Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial
    Comella, P
    Massidda, B
    Filippelli, G
    Palmeri, S
    Natale, D
    Farris, A
    De Vita, F
    Buzzi, F
    Tafuto, S
    Maiorino, L
    Mancarella, S
    Leo, S
    Lorusso, V
    De Lucia, L
    Roselli, A
    ANNALS OF ONCOLOGY, 2005, 16 (06) : 878 - 886
  • [39] Fluorouracil/folinic acid/oxaliplatinInterstitial lung disease in an elderly patient: case report
    Reactions Weekly, 2009, 1263 (1) : 18 - 19
  • [40] Biochemical modulation of fluorouracil: Comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial
    Polyzos, A
    Tsavaris, N
    Giannopoulos, A
    Bacoyiannis, C
    Papadimas, V
    Kalahanis, N
    Karatzas, G
    Kosmas, C
    Sakelaropoulos, N
    Archimandritis, A
    Papachristodoulou, A
    Kosmidis, P
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 38 (03) : 292 - 297
12345